Abstract
Background and aims Summarised in polygenic risk scores (PRS), the effect of common, low penetrant genetic variants associated with colorectal cancer (CRC), can be used for risk stratification.
Methods To assess the combined impact of the PRS and other main factors on CRC risk, 163,516 individuals from the UK Biobank were stratified as follows: 1. carriers status for germline pathogenic variants (PV) in CRC susceptibility genes (APC, MLH1, MSH2, MSH6, PMS2), 2. low (<20%), intermediate (20-80%), or high PRS (>80%), and 3. family history (FH) of CRC. Multivariable logistic regression and Cox proportional hazards models were applied to compare odds ratios (OR) and to compute the lifetime incidence, respectively.
Results Depending on the PRS, the CRC lifetime incidence for non-carriers ranges between 6% and 22%, compared to 40% and 74% for carriers. A suspicious FH is associated with a further increase of the cumulative incidence reaching 26% for non-carriers and 98% for carriers. In non-carriers without FH, but high PRS, the CRC risk is doubled, whereas a low PRS even in the context of a FH results in a decreased risk. The full model including PRS, carrier status, and FH improved the area under the curve (AUC) in risk prediction (0.704).
Conclusion The findings demonstrate that CRC risks are strongly influenced by the PRS for both a sporadic and monogenic background. FH, PV, and common variants complementary contribute to CRC risk. The implementation of PRS in routine care will likely improve personalized risk stratification, which will in turn guide tailored preventive surveillance strategies in high, intermediate, and low risk groups.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CM and EH are supported by the BONFOR-program of the Medical Faculty University of Bonn (O 147.0002). This study was supported (not financially) by the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) Project ID No 739547. ERN GENTU-RIS is partly co-funded by the European Union within the framework of the Third Health Pro-gramme ERN2016 Framework Partnership Agreement 2017 2021. DRB and PM are supported by the FNR INTER INTER/DFG/21/16394868. This research was also supported by the Instituto de Salud Carlos III and cofunded by European Social Fund ESF investing in your future (grants CM19/00099 and PID2019 111254RB I00) and from the European Union Horizon 2020 research and innovation program under the EJP RD COFUND EJP No 825575.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* shared
Conflict of interest statement: No potential conflicts (financial, professional, or personal) relevant to the manuscript.
Data Availability
Genome-wide genotyping data, exome-sequencing data, and phenotypic data from the UK Biobank are available upon successful project application. https://www.ukbiobank.ac.uk/
